Ambu ASAMBBY +10.36%84 ROE % is 7.92% as of Mar. 2026, which is 25% below its 10-year median of 10.53. GuruFocus rates AMBBY with a GF Score™ of 84/100 and a GF Value™ of $19.37 (Significantly Undervalued). Among 799 Medical Devices & Instruments companies, Ambu AS ranks better than 67.46% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ambu AS's annualized net income for the quarter that ended in Mar. 2026 was $74.9 Mil. Ambu AS's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $945.0 Mil. Therefore, Ambu AS's annualized ROE % for the quarter that ended in Mar. 2026 was 7.92%.
The historical rank and industry rank for Ambu AS's ROE % or its related term are showing as below:
AMBBY'
s ROE % Range Over the Past 10 Years
Min: 2.26 Med: 10.53 Max: 26.53
Current: 7.95
During the past 13 years, Ambu AS's highest ROE % was 26.53%. The lowest was 2.26%. And the median was 10.53%.
AMBBY's ROE % is ranked better than 67.46% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs AMBBY: 7.95
Ambu AS (OTCPK:AMBBY) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Ambu AS ROE % Related Terms
Ambu AS ROE % Historical Data
* Premium members only.
The historical data trend for Ambu AS's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Ambu AS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambu AS ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ambu AS's ROE % distribution charts can be found below:
* The bar in red indicates where Ambu AS's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ambu AS (AMBBY) has a ROE % of 7.92% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ambu AS and its competitors. This is 25% below median its historical median of 10.53. Over the past decade, Ambu AS's ROE % has ranged from 2.26 to 26.53. According to the industry distribution chart, Ambu AS ranks #260 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 32.5%.
Is Ambu AS's ROE % too high?
Ambu AS's current ROE % of 7.92% is 25% below median its 10-year median of 10.53. Over the past 10 years, this metric has ranged from a low of 2.26 to a high of 26.53. The Medical Devices & Instruments industry median ROE % is 2.42. Ambu AS's value of 7.92% is 227.3% above this industry median. Based on the distribution chart, Ambu AS ranks #260 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Ambu AS has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ambu AS's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ambu AS ranks #260 out of 799 companies for ROE %. This puts Ambu AS in the upper half of its industry. The industry median ROE % is 2.42. Ambu AS's value of 7.92% is 227.3% above this benchmark. Historically, Ambu AS's own ROE % has ranged from 2.26 to 26.53 over the past decade. While the company's 10-year median is 10.53 vs. the industry median of 2.42, Ambu AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambu AS's current ROE % of 7.92% is 227.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ambu AS and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambu AS's current ROE % is 7.92%, which is 25% below median its own 10-year median of 10.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambu AS stock overvalued right now?
Based on GuruFocus' analysis, Ambu AS (AMBBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.37, compared to a current price of $9.43 — trading 51.3% below its estimated fair value. The current ROE % is 7.92%, which is 25% below median its 10-year median of 10.53 and 227.3% above the Medical Devices & Instruments industry median of 2.42. Ambu AS's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ambu AS (AMBBY), the current ROE % is 7.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambu AS (AMBBY) Overvalued in 2026?
Based on GuruFocus' analysis, Ambu AS stock appears to be undervalued.
The current stock price of $9.43 is trading 51.3% below its estimated GF Value™ of $19.37.
GuruFocus considers Ambu AS to be Significantly Undervalued.
Key valuation signals for AMBBY:
ROE %: 7.92% (25% below median its 10-year median of 10.53)
GF Value™: $19.37 vs. price of $9.43 (51.3% below fair value)
Industry Position: 227.3% above the Medical Devices & Instruments median (#260 of 799)
No single metric tells the full story. See the AMBBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambu AS provides medical technology solutions. The company's business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.
84GF Score
Get the complete analysis for AMBBY
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMBBY has been successfully added to your 
